Search results
Showing 7396 to 7410 of 7707 results
In development [GID-TA10726] Expected publication date: TBC
November 2024: This evidence summary has been withdrawn because licensed products are now available.
In development [GID-TA10568] Expected publication date: TBC
In development [GID-TA11014] Expected publication date: TBC
In development [GID-TA11093] Expected publication date: TBC
This guidance has been updated and replaced by NICE technology appraisal guidance 1015.
This guidance has been updated and replaced by NICE interventional procedures guidance 794.
This guideline has been updated and replaced by the NICE guideline on head injury: assessment and management (NG232).
Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]
Discontinued [GID-TA10961]
Etanercept and infliximab for the treatment of psoriatic arthritis (TA104)
This guidance has been replaced by NICE technology appraisal guidance 199.
Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]
Discontinued [GID-TA10869]
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
In development [GID-TA11086] Expected publication date: TBC
In development [GID-TA11441] Expected publication date: TBC
Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]
Discontinued [GID-TA11261]
Multiple myeloma - bortezomib (consolidation therapy) [ID529]
Discontinued [GID-TAG320]